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Abstract
Background: Pneumococcal conjugate vaccines (PCV) reduce nasopharyngeal carriage of vaccine-serotype pneumococci
but increase in the carriage of non-vaccine serotypes. We studied the epidemiology of carriage among children 3–59
months old before vaccine introduction in Kilifi, Kenya.
Methods: In a rolling cross-sectional study from October 2006 to December 2008 we approached 3570 healthy children
selected at random from the population register of the Kilifi Health and Demographic Surveillance System and 134 HIV-
infected children registered at a specialist clinic. A single nasopharyngeal swab was transported in STGG and cultured on
gentamicin blood agar. A single colony of pneumococcus was serotyped by Quellung reaction.
Results: Families of 2840 children in the population-based sample and 99 in the HIV-infected sample consented to
participate; carriage prevalence was 65.8% (95% CI, 64.0–67.5%) and 76% (95% CI, 66–84%) in the two samples, respectively.
Carriage prevalence declined progressively with age from 79% at 6–11 months to 51% at 54–59 months (p,0.0005).
Carriage was positively associated with coryza (Odds ratio 2.63, 95%CI 2.12–3.25) and cough (1.55, 95%CI 1.26–1.91) and
negatively associated with recent antibiotic use (0.53 95%CI 0.34–0.81). 53 different serotypes were identified and 42% of
isolates were of serotypes contained in the 10-valent PCV. Common serotypes declined in prevalence with age while less
common serotypes did not.
Conclusion: Carriage prevalence in children was high, serotypes were diverse, and the majority of strains were of serotypes
not represented in the 10-valent PCV. Vaccine introduction in Kenya will provide a natural test of virulence for the many
circulating non-vaccine serotypes.
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Introduction
Pneumococcal disease is estimated to cause 826,000 deaths
among young children in developing countries and the majority of
these deaths occur in sub-Saharan Africa [1]. By comparison with
American children, African children have a higher incidence of
invasive pneumococcal disease (IPD) [2], experience disease at an
earlier age [3] and are affected by different serotypes, particularly
types 1 and 5 [4,5]. Nasopharyngeal carriage prevalence in
unvaccinated children is also higher in African ranging from 48%–
90% [6,7,8] compared to 35–52% in the UK/USA [9,10].
Pneumococcal conjugate vaccines (PCV) have substantially
reduced the incidence of IPD in children in the USA [11] and
have been shown in clinical trials to be effective in African
children, including those infected with HIV [12,13]. In opera-
tional use the effectiveness of these vaccines has been offset by
an increase in the rate of IPD caused by serotypes not included
in the vaccine [14]. In most settings this serotype replace-
ment disease has been small by comparison with the reduction in
disease caused by vaccine serotypes. However, in some popula-
tions, such as Alaska Native children [15], it has been more
substantial.
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e30787In 2011, Kenya introduced a 10-valent pneumococcal conju-
gate vaccine (PCV10) into the national childhood immunization
schedule. In Kilifi, prior to vaccine introduction, we established a
system of surveillance for childhood IPD to monitor the impact of
vaccine introduction on disease. To further understand the effect
of vaccine on carriage and transmission we also set up studies to
measure the prevalence, rate of acquisition and the rate of
clearance from the nasopharynx. Here we describe the serotype-
specific prevalence of carriage and the epidemiological risk factors
for prevalent carriage in the pre-vaccine era.
Methods
Study population
The study was conducted among children aged 3–59 months
who were registered residents of the Kilifi Health and Demo-
graphic Surveillance System (KHDSS) [16]. This is a longitudinal
surveillance of the population living in a well-defined geographic
area around Kilifi District Hospital (KDH), which is updated
through household visits, monitoring vital events and migration,
every four months. At the planning of the present study (1
st July
2006) the KHDSS area had a population of 41,651 aged 3–59
months.
Study design
The study was a rolling cross sectional survey conducted over a
period of 26 months and was linked to a study of carriage
clearance [17]. As the objective was to define the characteristics of
carriage at serotype-specific level, we aimed to recruit sufficient
children to observe at least 30 carriers of each serotype that was
responsible for colonizing at least 1% of carriers. Estimating
pneumococcal carriage prevalence in this age group at 75%, the
sample size was 4000 children. Each week we selected a small area
within the KHDSS and applied a random number to each child in
the population register for that area. We then selected the 10% of
children with the highest ranked numbers to study as a population-
based sample. The study moved across contiguous areas to
minimize travel for follow-up swabs [17].
HIV infection is a strong risk factor for IPD and is known to
modulate the epidemiology of carriage. As HIV prevalence among
children in Kilifi is low (,1%), and HIV testing has not been
universally applied across the KHDSS, we selected a group of
HIV-infected children directly from the register of the HIV clinic
at Kilifi District Hospital. At the clinic HIV-infection status was
defined by two rapid tests for HIV antibodies, except for children
,18 months of age, where it was defined by PCR. We approached
families of consecutive children registered at the clinic and resident
in the KHDSS either through home visits or at clinic visits, aiming
to recruit 100 children.
Children were excluded from either sample if they were no
longer resident in the KHDSS area, if their parent/guardian
declined consent, or if the child had an illness that prevented us
from taking a nasopharyngeal swab.
Laboratory methods
The study followed the guidelines of the WHO working group
on nasopharyngeal studies of Streptococcus pneumoniae [18]. Naso-
pharyngeal specimens were sampled using Dacron-tipped flexible
wire swabs passed via the anterior nares to the posterior
nasopharynx. The swab tips were immersed in skim-milk tryptone
glucose glycerol (STGG) transport medium, separated from its
handle with wire cutters and transported at ambient temperature
to the laboratory. Internal quality control of STGG was conducted
to assure sterility and the ability of the medium to support
pneumococcal growth. Swabs were cultured directly on arrival in
the laboratory. STGG samples were vortexed vigorously for
20 seconds, 10 ml was inoculated onto a blood agar plate
containing 2.5 mcg/ml gentamicin and incubated overnight at
37uCi n5 %C O 2. Pneumococci were identified by a-hemolysis,
optochin sensitivity and presence of capsule. We serotyped one
colony per plate using Quellung reaction and polyclonal rabbit
antisera (Statens Seruminstitut, Copenhagen, Denmark). Antisera
Table 1. Demographic distribution of the target population
and the study sample.
Number
selected
Included
in the
study
%
Included
in the
study
x
2 p-
value
Sex
Male 2143 1435 67.0
Female 2151 1405 65.3 0.255
Age (months)
3–23 1588 1023 64.4
24–41 1324 886 66.9
42–59 1382 931 67.4 0.184
Location of residence
Banda ra salama 145 99 68.3
Chasimba 275 208 75.6
Gede 168 138 82.1
Jaribuni 71 45 63.4
Junju 470 280 59.6
Kauma 128 102 79.7
Kilifi Township 580 293 50.5
Matsangoni 341 240 70.4
Mtwapa 168 132 78.6
Ngerenya 329 249 75.7
Roka 381 253 66.4
Sokoke 208 136 65.4
Takaungu-Mavueni 380 244 64.2
Tezo 399 245 61.4
Ziani 251 176 70.1 ,0.0005
Month of sampling
Jan 308 216 70.1
Feb 409 278 68.0
Mar 392 225 57.4
Apr 347 220 63.4
May 529 278 52.6
Jun 458 283 61.8
Jul 353 271 76.8
Aug 155 118 76.1
Sep 300 178 59.3
Oct 435 326 74.9
Nov 494 337 68.2
Dec 114 110 96.5 ,0.0005
Total 4294 2840 66.1
doi:10.1371/journal.pone.0030787.t001
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study.
Analysis
The analysis was undertaken in STATA v11.2 (StataCorp,
College Station, TX). To detect bias in the execution of the
sampling methods, we compared the demographic characteristics
of the consenting study participants with the randomly selected
sample of KHDSS using x
2. Pneumococcal carriage prevalence
was estimated from the cross-sectional survey and tested against
age and month of study by x
2 test for trend. For each population
sample a separate multivariable logistic regression model was
developed using backward stepwise regression, sequentially
excluding variables with p.0.05 on likelihood ratio test.
The Kenya Medical Research Institute/National Ethical
Review Committee and The Oxford Tropical Research Ethics
Committee approved the study. On behalf of minors/children
participants involved in this study, written informed consent was
obtained from their next of kin, carers or guardians.
Results
The cross-sectional survey of the population-based sample
began October 23, 2006 and ended December 2, 2008. We
selected 4,294 children at random from the KHDSS population
register and were able to find 3570 (83%) at home. The main
reasons for failing to identify children were the high out-migration
rate in the KHDSS [16], seasonal migration for farming, and the
Figure 1. Prevalence (and 95% CI) of nasopharyngeal carriage in children in Kilifi by age and by calendar month within the survey.
doi:10.1371/journal.pone.0030787.g001
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families located and invited to participate, 2840 (80%) consented
to the enrolment of their child into the study. Children who were
recruited to the study differed from those who were originally
selected on the month of sampling and location of residence but
not on age or sex (Table 1). The only prior use of pneumococcal
conjugate vaccine (7-valent PCV) in the KHDSS area was a study
of 300 children vaccinated as infants [19]; 14 of these were
recruited to the present study at ages varying between 4–34
months.
Children were recruited to the HIV-infected sample between
January 14, 2008 and July 21, 2008. Of 134 parents/guardians
approached, 99 (74%) consented for their children to participate.
There were no differences between those who did and did not
consent with respect to age, sex, location or month of sampling (all
p.0.05). The HIV-infected sample did not differ from the
population-based sample on age in years (p=0.58) but did differ
on sex; the proportion of males was 50.5% (1435/2840) in the
population-based sample and 69% (69/99) in the HIV-infected
sample (p,0.0005). None of the HIV-infected children had
previously received PCV.
Overall, 1868 (65.8%, 95%CI 64.0–67.5%) of the 2840
nasopharyngeal swab cultures from the population-based sample
were positive for Streptococcus pneumoniae. Carriage prevalence
declined markedly with age (x
2 test for trend 70.9, p,0.0005)
although it was lower in children aged 3–5 months than those aged
6–11 months (Figure 1, Table S2). Carriage prevalence did not
vary by sex (p=0.44, Table S2) but did vary by administrative
location across the KHDSS, from 49% to 79% (x
2 (14) 84.0,
p,0.0005, Table S2), and by month of sampling, from 51% in
January to 83% in July (x
2 (11) 113.7, p,0.005, Figure 1). The
monthly prevalence of carriage was not associated with total
monthly rainfall, nor with monthly medians of daily measurements
of relative humidity, minimum and maximum daily temperature
taken in Kilifi across the 26 months of the study (Figure S1).
In the HIV-infected sample, 75 (76%, 95%CI 66–84%) of the
99 swab cultures were positive for pneumococcus. Carriage
prevalence did not vary significantly by sex, age, month of
sampling or anti-retroviral treatment (p.0.2 for all, Table 2). By
comparison with the population-based sample, the colonization
prevalence in the HIV-infected group was higher (65.8% vs. 76%,
Table 2. Carriage prevalence by age, sex and antiretroviral
drug use among HIV-infected children.
Variable Sample Carriers
Prevalence
(%) 95% CI x
2 p value
Sex
Male 68 50 74 61–83
Female 31 25 81 63–93 0.44
Age (m)
3–23 33 22 66 48–82
24–41 31 24 77 59–90
42–59 35 29 83 66–93 0.29
Antiretroviral therapy
Yes 40 31 75 62–85
No 59 44 78 62–89 0.74
doi:10.1371/journal.pone.0030787.t002
Table 3. Risk factors for prevalent nasopharyngeal carriage of S. pneumoniae.
Risk factor Sample Carriers OR 95% CI aOR 95% CI
Male sex 1435 934 0.94 0.81–1.10
Cough in the last 2 weeks? 1420 1079 2.53 2.15–2.96 1.55 1.26–1.91
Coryza in the last 2 weeks? 1684 1286 3.18 2.71–3.73 2.62 2.12–3.34
Child taken antibiotics in the last 2 weeks? 111 67 0.78 0.53–1.16 0.53 0.34–0.81
Child taken Fansidar in the last 2 weeks? 30 17 0.68 0.33–1.40
Child hospitalized in the last month? 8 5 0.87 0.21–3.63
Child sleeps in the cooking room? 496 344 1.22 0.99–1.50
Cooking fuel
firewood 2761 1814 1.00
gas 10 8 2.09 0.44–9.85
charcoal 60 41 1.13 0.65–1.95
paraffin 9 5 0.65 0.17–2.44
Smoker in the house 517 368 1.36 1.10–1.67
Household member hospitalized in last month 18 12 1.04 0.39–2.78
Study time (per month) 1.00 0.99–1.01 0.98 0.96–0.99
No. of other children (aged 0–2 y) in the house (per child) 0.82 0.71–0.95
No. of other children (aged 3–4 y) in the house (per child) 1.11 0.97–1.28
No. of other children (aged5–9 y) in the house (per child) 1.05 0.97–1.14
No. of other children (aged 10–14 y) in the house (per child) 1.01 0.95–1.07
No. of children (aged #5 y) sharing a bed with child (per child) 0.95 0.84–1.07
OR Odds Ratio; aOR adjusted Odds Ratio. Variables included in the final model but not displayed here are age (6 monthly strata), month of sampling and fieldworker
taking the sample (n=9). The full analysis is displayed in Table S2. The final model fit was tested using Hosmer-Lemeshow x
2 in 10 covariate strata (p=0.95).
doi:10.1371/journal.pone.0030787.t003
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restricting the analysis to the period when survey of both samples
was concurrent, the odds of colonization were significantly higher
in the HIV-infected sample (OR 2.21, 95% CI 1.35–3.61).
Risk factors that were positively associated with nasopharyngeal
carriage of S. pneumoniae were a history of coryza or cough in the
previous two weeks; children who reported taking antibiotics in the
previous two weeks had lower odds of carriage (Table 3, Table S1).
There were no significant interactions between variables in the
final model. The Hosmer-Lemeshow x
2 test was non-significant (df
8, p=0.95) suggesting a good fit of the model to the data. None of
the risk factors were associated with carriage in the HIV-infected
sample.
Although the prevalence of carriage varied from month to
month we did not find any evidence of a trend in prevalence over
time in univariate analyses (x
2 test for trend by month p=0.71).
However, in the multivariable analysis of carriage, after adjusting
for potential confounders, we observed a 2% decline in carriage
per month of observation (Table 3).
Among the population-based sample, we isolated a total of 53
different serotypes from all the swab cultures. The carriage
prevalence of individual serotypes ranged from 10% to 0.03%
(Table 4, Table S2). Among HIV-infected children, we isolated a
total of 23 different serotypes and carriage prevalence of any one
serotype ranged from 14% to 1%. The distribution of serotypes in
the population-based sample and the HIV-infected sample did not
differ (x
2 (28)=33.4, p=0.22). The ten most common serotypes in
the population-based sample comprised 67.5% of all isolates; in
the HIV-infected sample they comprised 79% (p=0.044)
suggesting that common serotypes dominate more effectively in
HIV-infected children.
Variation in serotype prevalence by age is difficult to interpret
because of the large number of strata, in this case 53 serotypes.
Confining the analysis to the 20 most frequently observed
serotypes, and collapsing all other types to ‘other’, an association
with age in years was observed (x
2 (80)=109, p=0.017). We
investigated how changes in serotype distributions with age are
related to the overall prevalence of a serotype. We categorized the
most highly prevalent 20 serotypes into 4 strata of 5 serotypes
based on their prevalence ranking in the whole population-based
survey; all remaining serotypes were categorized as ‘other’. The
distribution of the prevalence of these strata against age in years is
highly significant (x
2 (20) 106, p,0.0005, Figure 2). It illustrates a
fall in the prevalence of common serotypes against age that is not
matched by the mixture of less common serotypes.
The original formulation of PCV contained antigens for seven
serotypes, 4, 6B, 9V, 14, 18C, 19F and 23F (PCV7). The present
vaccines have extended this formulation to include serotypes
1, 5 and 7F (PCV10) and then, in addition, 3, 6A and 19A
(PCV13). In the population-based sample, the proportions of all
colonizing isolates that were of serotypes represented in PCV7,
PCV10 and PCV13 were 41% (95% CI 38–43%), 42% (39–44%)
and 59% (57–61%), respectively. In the HIV-infected sample they
were 43% (31–55%), 43% (31–55%) and 67% (55–77%),
respectively.
Discussion
The prevalence of pneumococcal carriage in children in Kilifi is
high – despite the insensitivity of sampling and laboratory
detection methods [20], two-thirds of all children aged 3–59
months were found to be carriers. Carriage prevalence decreased
steadily with age and varied significantly by season and HIV-
infection. Carriage prevalence also varied by residential location
though this was inherently linked to season by the rolling cross-
sectional design of the study. We observed 53 different serotypes,
in a well-defined human population of 250 000, maintained at
widely different frequencies - a degree of diversity also observed in
a similar study in The Gambia [21]. Forty-three of these serotypes,
accounting for 58% of all the isolates carried, are not included in
the 10-valent PCV which was introduced into the Kenyan
immunization schedule in 2011.
Our estimate of pneumococcal carriage prevalence (66%)
among children aged 3–59 months is similar to prevalence
estimates among children aged ,5 years in Pakistan (62%) [22]
and Uganda (62%) [23] but lower than the prevalence in
Mozambique (87%) [5], The Gambia (.90%) [24] and Malawi
(84%) [25]. Each of these studies sampled sick children presenting
to hospital. Estimates of carriage prevalence among healthy
children were much lower, at 22% in Kenya, [26] and 48% in
Malawi, [8] but even in these studies the children were selected
Table 4. Serotype carriage prevalence among population-based
and HIV-infected samples.
Population-based sample HIV-infected sample
Serotype N Prevalence (%) N Prevalence (%)
19F 283 10.0 14 14
6A 237 8.3 13 13
6B 184 6.5 5 5
23F 117 4.1 9 9
11A 90 3.2 1 1
14 85 3.0 1 1
35B 84 3.0 2 2
23B 70 2.5 1 1
10A 56 2.0 0 0
15B 54 1.9 3 3
19A 53 1.9 1 1
9V 51 1.8 3 3
13 49 1.7 3 3
15A 49 1.7 2 2
15C 43 1.5 2 2
34 38 1.3 0 0
3 34 1.2 4 4
16F 34 1.2 0 0
18C 29 1.0 0 0
19B 25 0.9 2 2
7C 23 0.8 1 1
20 21 0.7 3 3
23A 19 0.7 1 1
21 18 0.6 0 0
35A 15 0.5 0 0
1 13 0.5 0 0
33B 13 0.5 0 0
4 12 0.4 0 0
Other types 69 2.4 4 4
All types 1,868 65.8 75 76
There is no evidence of a difference between the HIV-infected and population-
based samples in the distribution of serotypes (x
2 (28) 33.4, p=0.223).
doi:10.1371/journal.pone.0030787.t004
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villages in The Gambia the prevalence was estimated at over 90%
[27]. The higher prevalence of carriage among healthy children in
The Gambia may be a function of the different climates, sampling
in different seasons, or of differing social organization; life in The
Gambia is based around villages while, in Kilifi, the population
live in more widely dispersed patterns.
A key determinant of the prevalence of pneumococcal carriage
in children is age. In our study carriage prevalence reached a peak
of 79% in the children aged 6–11 months and then declined
steadily to 51% among those aged 54–59 months. The rise
between 3–5 and 6–11 months is probably attributable to
cumulative exposure since birth. The subsequent decline in
prevalence is attributable to an age-related increase in clearance
rates. In the accompanying study [17] we observed a constant rate
of acquisition from 3–59 months of age but a progressive increase
in clearance rates, reducing the mean duration of a colonization
episode from 45 days to 21 days. We have also shown here that the
prevalence of more commonly encountered serotypes declined
markedly with age but the prevalence of less common serotypes
did not. This observation is compatible with acquired serotype-
specific immunity, developed on the basis of prior exposure
[28,29], although to date the impact of serotype-specific immunity
has been documented only for a few serotypes, and only in
reducing acquisition, rather than shortening duration [28,29,30].
As the most common serotypes are also those with the longest
durations, the same epidemiological pattern would also be
predicted by species-specific immunity, such as that mediated by
CD4+ Th17 cells, where the action of immune clearance occurs
after a lag interval [31].
A history of upper respiratory tract infection (URTI) symptoms,
cough or coryza, during the two weeks prior to nasopharyngeal
sampling was strongly associated with carriage in this study as in
several previous studies [6,32,33]. Unfortunately the cross-
sectional study design does not allow us to differentiate between
several explanations, which include: (1) that coryza physically
enhances the trapping, adherence and growth of pneumococci in
the nasopharynx; (2) that coryza may augment the sensitivity of
swab sampling of the nasopharynx; (3) that pneumococcal
colonization leads directly to the symptoms of an URTI; or (4)
that viral URTIs and pneumococcal carriage are both indepen-
dently associated with seasonal factors, such as cold weather and
crowding, leading to a false association.
In Kenya, carriage prevalence has been observed to be higher
among HIV-infected than among HIV-uninfected adults [34];
elsewhere pediatric serotypes (e.g. 6B, 14) have been observed
more frequently in HIV-infected adults than HIV-uninfected
adults [35]. Our ability to investigate these associations in children
was constrained by the low prevalence of HIV-infection in Kilifi.
HIV-infection is identified in 4–5% of antenatal mothers in Kilifi
[36] but there is an effective program of prevention of mother-to-
child transmission. Therefore, we recruited a separate sample of
children, selected on the basis of known HIV-infection, and did
not test our population-based sample for HIV. Although the
samples were derived from different sources, and there is a small
degree of misclassification in one, the study should be sensitive to
Figure 2. Prevalence of carriage of common and less common pneumococcal serotypes by age.
doi:10.1371/journal.pone.0030787.g002
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had a two-fold higher odds of carriage than the unselected
population but we did not observe any difference in the serotype
distribution of colonization with HIV prevalence.
Because of the inherent difficulties and cost of detecting multiple
serotype carriage in the laboratory and the large scale of this field
study, we limited our investigation to studying a single serotype per
swab. This decision has a consequence in estimating the
prevalence. Assuming that, in multiply colonized individuals, the
probability of sampling a strain (by physical swabbing and by
selection of a colony from a culture plate) is proportional to the
frequency of that serotype type in that nasopharynx then the study
is effectively a random sample of strains from a random sample of
human hosts. This will provide an accurate estimate of the relative
prevalence of different serotypes, at an ecological level, but will
underestimate the absolute prevalence of colonization by each
serotype in the population.
A current question of public health interest is whether the
benefits of introducing PCV7 into routine childhood immuniza-
tion programs in developing countries will be undermined by an
increase in the incidence of non-vaccine serotype disease. The
potential for ‘serotype replacement disease’ is determined by the
circulation of non-vaccine serotypes and the propensity of those
serotypes to cause disease once they have colonized the
nasopharynx [37]. In Kilifi, 59% of carriers harbor serotypes that
are not included in the 7-valent vaccine and this appears to be
consistent over time in this area [6] and across the continent.
Similar figures for The Gambia, Mozambique, Malawi and South
Africa are in the range 51–64% [5,7,25,38]. The invasive potential
of these serotypes has not been evaluated in a developing country
but serotypes that have been found to increase invasive disease in
developed countries, e.g. 3, 7F, 15B/C, 19A, 22F, 33F and 38
[39,40,41,42,43,44] are currently carried by 7% of all children in
Kilifi.
Kenya introduced PCV10 into the routine childhood immuni-
zation program in 2011. The three additional serotypes in this
formulation, 1, 5 and 7F, are important causes of invasive
pneumococcal disease in Africa [4,12] but they are carried by less
than 1% of children in this study. Beyond the PCV10 serotypes we
detected pneumococcal strains from 43 different serotypes
accounting for 58% of all prevalent carriage episodes. Operational
use of conjugate pneumococcal vaccines in Kenya, justified by
strong evidence of efficacy against invasive pneumococcal disease
[12,13], will provide an interesting natural test of the invasive
potential of the many non-vaccine serotypes circulating in this
population.
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